Understanding Your Wegovy Versus Mounjaro Treatment Options
Wegovy Versus Mounjaro: Starter Dose Protocol Differences
When comparing Wegovy versus Mounjaro starter doses, the fundamental difference lies in their escalation schedules and mechanisms. Wegovy (semaglutide) follows a structured 16-week dose escalation starting at 0.25mg weekly for the first four weeks, designed to minimise side effects whilst allowing your body to adjust to this GLP-1 receptor agonist. This prescription-only medicine requires careful titration to reach the maintenance dose of 2.4mg by week 17.
Mounjaro (tirzepatide) operates as a dual GIP and GLP-1 receptor agonist with its own distinct starter protocol. Understanding these differences is crucial when evaluating Wegovy versus Mounjaro options, as each treatment's starter phase impacts both tolerability and long-term success. Your prescriber at EverydayMeds can assess which starter dose protocol aligns with your medical history and weight management goals during the clinical assessment process.
Starter Dose Pricing: Wegovy Versus Mounjaro Cost Analysis
For patients beginning their Wegovy versus Mounjaro comparison, starter dose pricing represents a significant consideration. Wegovy's 0.25mg starter dose costs £79.99 for new customers using code FIRST40 at checkout, covering your first four weeks of treatment. Our Intro Duo bundle (0.25mg and 0.5mg pens) provides two months of treatment for £169.99, ensuring seamless progression through your initial dose escalation without separate orders.
When evaluating Wegovy versus Mounjaro starter costs, consider the complete escalation journey rather than individual pen prices. Our bundle options provide convenience through Reliable Supply continuity, with the Intro Trio (0.25mg, 0.5mg, and 1mg) offering three months of progressive dosing for £299.99. Both treatments are available through our GPhC-registered pharmacy (#9012878) with identical prescriber assessment and delivery processes, allowing cost comparison alongside clinical suitability.
Clinical Evidence: Wegovy Versus Mounjaro Trial Data
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results establish Wegovy's efficacy when properly titrated through the starter dose protocol to maintenance levels.
When comparing Wegovy versus Mounjaro clinical evidence, both treatments have demonstrated significant efficacy in their respective trial programmes, though direct head-to-head comparisons remain limited due to different trial designs and populations. Your prescriber can discuss how these clinical findings may relate to your individual circumstances during the assessment process.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone produced in your intestines. This mechanism may help reduce appetite and promote feelings of fullness after smaller meals, whilst potentially reducing food cravings by acting on brain appetite centres. The starter dose of 0.25mg allows your body to gradually adjust to these hormonal changes, minimising potential side effects like nausea whilst building tolerance. Unlike Mounjaro's dual receptor approach, Wegovy specifically targets GLP-1 receptors, providing a focused mechanism that has been extensively studied in weight management contexts. This targeted approach requires the structured dose escalation beginning with the 0.25mg starter dose to achieve optimal therapeutic effects.
Your Wegovy Ordering Process at EverydayMeds
Starting your Wegovy versus Mounjaro evaluation begins with our streamlined three-minute online clinical assessment, designed to capture relevant medical history and current medications. Our qualified prescribers review applications within three working days (or 24 hours with express service), ensuring thorough evaluation of your suitability for either treatment option. Once approved, your Wegovy starter dose ships via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) ensures all prescriptions meet UK regulatory standards whilst providing ongoing clinical support throughout your treatment journey. This comprehensive process applies equally whether you choose Wegovy or Mounjaro, maintaining consistent quality and safety standards.
Storage and Practical Considerations
Wegovy requires refrigeration at 2-8°C before first use but offers superior travel convenience with six weeks room temperature stability below 30°C once removed from the fridge. This storage advantage over Mounjaro's 21-day room temperature limit makes Wegovy particularly suitable for patients with active lifestyles or frequent travel requirements. The FlexTouch pen system provides precise dosing with clear dose windows, making the weekly injection process straightforward throughout your dose escalation. Each 0.25mg starter pen contains four weekly doses, perfectly aligned with the first month of treatment before progressing to 0.5mg in weeks five through eight. Understanding these practical aspects helps inform your Wegovy versus Mounjaro decision beyond purely clinical considerations.
First-Time Patient Support: Wegovy Versus Mounjaro Starter Experience
Beginning weight management treatment can feel daunting, which is why our Wegovy versus Mounjaro starter programmes include comprehensive patient education and ongoing support. New Wegovy patients receive detailed injection technique guidance, side effect management strategies, and realistic expectation setting for the initial weeks of treatment. Most patients experience gradual appetite changes during the 0.25mg starter phase, with some mild nausea that typically resolves as your body adjusts to the medication.
Our clinical team provides personalised advice on optimising your starter dose experience, including meal timing recommendations and lifestyle modifications that complement either Wegovy or Mounjaro treatment. This support structure ensures you feel confident and informed throughout your initial treatment phase, regardless of which option proves most suitable for your circumstances. The goal is creating a sustainable foundation for long-term weight management success from day one of treatment.
Making Your Decision: Next Steps with EverydayMeds
Your Wegovy versus Mounjaro decision ultimately depends on individual factors including medical history, lifestyle preferences, and clinical suitability as determined by our qualified prescribers. Both treatments represent evidence-based approaches to weight management when used alongside reduced-calorie diet and increased physical activity, with distinct mechanisms and protocols to consider. Starting your journey requires completing our clinical assessment, where you can discuss both options with our medical team to determine the most appropriate treatment path. New customers benefit from code FIRST40 at checkout, whilst returning patients use code DOSE25 for continued savings on their chosen treatment. Our commitment extends beyond initial prescribing to ongoing support throughout your weight management journey, ensuring you have expert guidance every step of the way.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
